A lot of patients have started coming to consultations asking the same question: “Have you heard of Boey?” Some are calling it TrenibotE. Others have seen it referenced online as BoNT/E or trenibotulinumtoxinE. Whatever name they’ve encountered, what they’re really asking about is the same thing: a new type of neuromodulator that reportedly works faster and wears off sooner than traditional Botox-style treatments.
Here’s what the current science says, where it stands clinically, and why we think it’s worth understanding before it potentially becomes available.
What Is Boey Toxin?
Boey is the brand name used in official regulatory filings by Allergan Aesthetics, an AbbVie company. Its full scientific name is trenibotulinumtoxinE, often shortened to TrenibotE or referred to as BoNT/E in clinical literature. It’s an injectable neuromodulator designed to temporarily relax the muscles that create frown lines between the eyebrows, what are clinically called glabellar lines.
What distinguishes Boey from existing wrinkle relaxers isn’t so much what it does, but how quickly it acts and how briefly those effects last. Data from Phase 3 clinical trials suggest it may produce visible results in as little as 8 hours after treatment, with effects lasting approximately 2 to 3 weeks.
For comparison, Botox and Dysport typically take 3 to 5 days to produce noticeable results and last 3 to 4 months.
Boey, TrenibotE, and BoNT/E: Why the Names Matter
The overlapping names can be genuinely confusing, so it helps to understand what each refers to.
TrenibotE and trenibotulinumtoxinE are the generic and scientific names for the molecule. BoNT/E is the abbreviation commonly used in research, referring to botulinum neurotoxin serotype E. Boey is the brand name Allergan Aesthetics submitted for regulatory review, and it’s the name that appeared in the May 2026 positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). If you’ve searched any of these terms, you’ve been looking for the same product.
It’s worth noting: Boey has not yet received US FDA approval. If you’ve seen it described online under any name as currently available in the United States, that’s not accurate as of now.
How Is Boey Different From Botox?
The difference starts at the molecular level, and it matters clinically.
Botox, Dysport, Xeomin, Jeuveau, and Daxxify are all made from botulinum neurotoxin serotype A. Boey (TrenibotE) is the first aesthetic neuromodulator made from botulinum neurotoxin serotype E, a different family entirely.
Both serotypes work by blocking signals at the neuromuscular junction, temporarily preventing the muscle contractions that create dynamic wrinkles. But serotype E binds at a different site on the same target protein (SNAP-25), and that biochemical distinction produces a meaningfully different clinical timeline.
The Phase 3 trial data showed:
- Onset: as early as 8 hours after injection (the earliest point assessed in the studies)
- Duration: approximately 2 to 3 weeks
- Safety: treatment-emergent adverse events were similar to placebo across both single and repeat treatments, in a clinical program of more than 2,100 patients
These studies evaluated TrenibotE specifically for moderate to severe glabellar lines, with two pivotal Phase 3 studies and an open-label safety study. All primary and secondary endpoints were met.
Why a Fast-Acting, Shorter-Lasting Toxin Could Matter
The short duration isn’t a limitation. For some patients, it’s exactly the point.
There’s a real and documented group of people who are interested in neuromodulators but hesitant because they’re worried about looking different for three to four months if they don’t love the result. That’s a legitimate concern, and it keeps a lot of first-time patients on the fence. A treatment that wears off in two to three weeks gives someone a lower-stakes way to experience what a neuromodulator does on their own face.
There’s also the event-timing use case. Someone preparing for a wedding, a reunion, or a high-profile professional appearance a couple of weeks away may want a refreshed look that doesn’t outlast the occasion by months. In theory, a short-acting injectable could be scheduled more precisely for that kind of window.
Some clinicians have also described TrenibotE as a potential “gateway” treatment, a way for hesitant patients to try the category, see results they’re comfortable with, and then transition to a longer-lasting option.
That said, shorter duration isn’t better for everyone. Most patients who already appreciate their neuromodulator results genuinely don’t want them to last only two to three weeks. And for anyone concerned about an unwanted result, two to three weeks of discomfort isn’t a meaningfully better experience than three to four months. The shorter window reduces commitment, but it doesn’t eliminate it.
Who Might Be Interested in Boey or TrenibotE?
Based on available clinical data, TrenibotE has been studied in adults with moderate to severe glabellar lines. Those are the vertical creases between the brows that appear when you frown, often called the “11s.”
Depending on anatomy, goals, skin type, medical history, muscle strength, facial movement patterns, and provider assessment, patients who may eventually be good candidates include:
- First-time neuromodulator patients who are curious but cautious about a long-duration commitment
- Patients who’ve had results they didn’t love and want a shorter experience if they try again
- Patients timing treatment around a specific near-term event
- Patients looking for a lower-commitment introduction to the aesthetic benefits of wrinkle relaxers
This is not a comprehensive candidate list, and no product is right for every patient. A proper evaluation is the only way to know whether Boey, or any neuromodulator, makes sense for a given person’s goals.
Is Boey Available Yet?
Not in the United States.
AbbVie submitted a Biologics License Application (BLA) to the FDA in April 2025. In April 2026, the FDA issued a Complete Response Letter (CRL), indicating it had questions related to manufacturing processes. The letter did not request additional clinical studies, meaning the safety and efficacy data the company submitted were not in question. AbbVie has stated it plans to respond to the FDA’s manufacturing questions in the coming months and is working toward completing the review process.
In Europe, the process is further along. In May 2026, the EMA’s CHMP issued a positive opinion recommending approval of Boey for the temporary improvement of moderate to severe glabellar lines across 30 EU and EEA markets. A formal European Commission decision is expected in the coming months, which would make Boey the first commercially available serotype E neuromodulator for aesthetic use anywhere in the world.
US approval remains pending. Whether and when that happens will depend on how the FDA review unfolds.
Aion Aesthetics’ Perspective on New Neuromodulators
We pay attention to what’s coming down the pipeline because our patients are paying attention to it, and because genuinely new categories of treatment are worth understanding before they arrive.
Boey is interesting to us for the same reason Daxxify was interesting when it was in development: it represents a biologically distinct approach, not just a reformulation. A serotype E toxin has never been available for aesthetic use. If it reaches the US market with the safety and onset profile the Phase 3 data suggest, it adds something that doesn’t currently exist in our toolkit.
But more options don’t change the fundamentals of good aesthetic medicine. A faster neuromodulator doesn’t help a patient whose concern is volume loss, bone structure, or skin texture. A shorter-acting one isn’t more useful for someone who already knows what they want and comes back every three to four months like clockwork. Matching the right product to the right patient is the job, and that doesn’t change regardless of how many products are available.
Our approach to any injectable treatment is built around understanding the anatomy in front of us and the goal the patient is trying to achieve. The target isn’t maximum relaxation. It’s soft, natural-looking refinement that respects how the face moves. That’s the standard we’d apply to Boey if and when it becomes available, just as we apply it to everything we offer now.
Final Takeaway
Boey, known in clinical and research settings as TrenibotE or BoNT/E, is one of the most clinically distinctive products in the neuromodulator pipeline. Its rapid onset and short duration are genuinely different from anything currently on the US market, and they address a real patient need that existing treatments don’t fully serve.
It’s not FDA-approved yet, and when approval will come remains uncertain. But the European regulatory path is moving, the US review is ongoing, and AbbVie has indicated the clinical data are not in question. This is a treatment worth tracking.
If you’re curious about Boey, TrenibotE, or neuromodulator options that are currently available, Aion Aesthetics is accepting consultations on the Upper East Side. We’re happy to talk through what makes sense for your goals now, and what may be worth considering when the landscape changes.
Frequently Asked Questions
What is Boey toxin?
Boey is the brand name for trenibotulinumtoxinE (also called TrenibotE or BoNT/E), an injectable neuromodulator developed by Allergan Aesthetics (AbbVie). It’s the first aesthetic neuromodulator made from botulinum neurotoxin serotype E, distinguishing it from Botox, Dysport, Xeomin, Jeuveau, and Daxxify, which are all serotype A. Published Phase 3 data indicate an onset as early as 8 hours after injection and a duration of approximately 2 to 3 weeks.
Is Boey the same as Botox?
No. Both relax muscles by temporarily blocking signals at the neuromuscular junction, but they’re derived from different botulinum toxin serotypes (E versus A) and act on the same target protein at different cleavage sites. The practical result is that Boey has a faster reported onset and a much shorter duration than traditional serotype A products like Botox or Dysport.
Is Boey (TrenibotE) FDA approved?
Not as of June 2026. AbbVie submitted a Biologics License Application to the FDA in April 2025. In April 2026, the FDA issued a Complete Response Letter related to manufacturing questions, with no additional clinical studies requested. The company plans to respond in the coming months. In Europe, the EMA’s CHMP issued a positive opinion recommending approval in May 2026, with a formal European Commission decision pending.
How long does Boey last?
Phase 3 clinical data suggest the effects of TrenibotE last approximately 2 to 3 weeks. This is significantly shorter than the 3 to 4 months typically associated with Botox, Dysport, Xeomin, Jeuveau, or Daxxify. Individual results would vary based on anatomy, muscle activity, and other factors.
Who might be a good candidate for Boey?
TrenibotE has been studied in adults with moderate to severe glabellar lines (the frown lines between the eyebrows). Patients who may eventually be well-suited include first-time neuromodulator users who want a low-commitment option, patients timing treatment around a specific near-term event, or those who’ve had results they weren’t fully happy with and want a shorter experience. Candidacy depends on a full evaluation by a qualified provider, accounting for anatomy, goals, skin type, medical history, muscle strength, and facial movement patterns.
Where can I find Boey or TrenibotE in New York City?
Boey is not yet FDA-approved or commercially available in the United States, including New York City. Patients in NYC who are curious about neuromodulator options currently available, or who want to be informed when Boey reaches the US market, can schedule a consultation at Aion Aesthetics on the Upper East Side to discuss what’s appropriate for their goals.
